BioRegenx, Inc.
BRGX
$0.01
$0.0013.92%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.85M | 1.93M | 2.02M | 2.31M | 2.34M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.85M | 1.93M | 2.02M | 2.31M | 2.34M |
| Cost of Revenue | 350.90K | 421.80K | 454.80K | 625.50K | 681.80K |
| Gross Profit | 1.50M | 1.51M | 1.56M | 1.68M | 1.66M |
| SG&A Expenses | 2.05M | 3.36M | 3.17M | 4.22M | 7.09M |
| Depreciation & Amortization | -25.00K | 562.10K | 1.12M | 1.12M | 1.12M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.37M | 4.34M | 4.75M | 5.97M | 8.89M |
| Operating Income | -519.10K | -2.41M | -2.73M | -3.66M | -6.55M |
| Income Before Tax | -1.54M | -18.93M | -19.24M | -20.17M | -23.05M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.54 | -18.93 | -19.24 | -20.17 | -23.05 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.54M | -18.93M | -19.24M | -20.17M | -23.05M |
| EBIT | -519.10K | -2.41M | -2.73M | -3.66M | -6.55M |
| EBITDA | -418.90K | -1.78M | -1.53M | -1.93M | -4.33M |
| EPS Basic | 0.00 | -0.02 | -0.02 | -0.02 | -0.03 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| EPS Diluted | 0.00 | -0.02 | -0.02 | -0.02 | -0.03 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Average Basic Shares Outstanding | 3.84B | 3.74B | 3.74B | 3.73B | 3.54B |
| Average Diluted Shares Outstanding | 3.84B | 3.74B | 3.74B | 3.73B | 3.54B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |